Pediatric Oncology
Blood donor characteristics linked to outcomes of very low-birth-weight infants
Very low-birth-weight infants who received blood transfusions from female donors had a lower risk for mortality and/or serious morbidity than those who received transfusions from male donors, study results showed.
Children’s hospital appoints chief of pediatric hematology-oncology division
Oren J. Becher, MD, has been appointed chief of the Jack Martin division of pediatric hematology-oncology at Mount Sinai Kravis Children’s Hospital.
Radiation therapist finds new outlet to fight cancer with children’s book fundraiser
Cierra Aber is a helper.
FDA grants fund trials of treatments for brain cancer
The FDA awarded 11 grants worth more than $25 million to fund clinical trials of medical products intended to treat patients with rare diseases.
Children with cancer more likely to have severe COVID-19 illness
Children with cancer who contracted COVID-19 developed more serious infections and had a greater likelihood of hospitalization or death than the general pediatric population, according to study results published in The Lancet Oncology.
APPs key to helping children, families transition to ‘new normal’ after treatment
The completion of cancer-directed therapy is a time for celebration.
7 important updates for Childhood Cancer Awareness Month
September is Childhood Cancer Awareness Month.
Cisplatin-induced hearing loss common among very young children early in treatment
Young children with cancer who received cisplatin chemotherapy had a higher incidence of cisplatin-induced hearing loss than older children, according to study results published in Cancer.
Yale New Haven Children’s Hospital appoints chief of pediatric hematology
Lakshmanan Krishnamurti, MD, has been appointed chief of pediatric hematology, oncology and bone marrow transplant at Yale New Haven Children’s Hospital.
Remission by ’whatever means’: The role of CAR-T, HSCT for younger patients with ALL
Clinicians who treat blood cancers often disagree whether chimeric antigen receptor T-cell therapies are a potential replacement for hematopoietic stem cell transplant.